<SUBMISSION>
<ACCESSION-NUMBER>0000950144-04-009486
<TYPE>SC 13D/A
<PUBLIC-DOCUMENT-COUNT>1
<FILING-DATE>20041001
<DATE-OF-FILING-DATE-CHANGE>20041001
<FILED-BY>
<COMPANY-DATA>
<CONFORMED-NAME>FALIKS AVIEL
<CIK>0001271966
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>SC 13D/A
</FILING-VALUES>
<MAIL-ADDRESS>
<STREET1>101 SUMMERS ST
<STREET2>APT 414
<CITY>STAMFORD
<STATE>CT
<ZIP>06901
</MAIL-ADDRESS>
</FILED-BY>
<SUBJECT-COMPANY>
<COMPANY-DATA>
<CONFORMED-NAME>ACCUIMAGE DIAGNOSTICS CORP
<CIK>0001089799
<ASSIGNED-SIC>7371
<IRS-NUMBER>330713615
<STATE-OF-INCORPORATION>NV
<FISCAL-YEAR-END>0930
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>SC 13D/A
<ACT>34
<FILE-NUMBER>005-79375
<FILM-NUMBER>041059410
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>501 GRANDVIEW DRIVE
<STREET2>STE 100
<CITY>SOUTH SAN FRANCISCO
<STATE>CA
<ZIP>94080
<PHONE>6508750192
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>501 GRANDVIEW DRIVE
<STREET2>STE 100
<CITY>SOUTH SAN FRANCISCO
<STATE>CA
<ZIP>94080
</MAIL-ADDRESS>
</SUBJECT-COMPANY>
<DOCUMENT>
<TYPE>SC 13D/A
<SEQUENCE>1
<FILENAME>g91158sc13dza.htm
<DESCRIPTION>ACCUIMAGE DIAGNOSTICS CORP.
<TEXT>
<HTML>
<HEAD>
<TITLE>AccuImage Diagnostics Corp.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<TABLE align="right" width="160" border="1" cellspacing="0" cellpadding="1">
<TR><TD align="center" nowrap><FONT size="2">OMB APPROVAL</FONT></TD></TR>
<TR><TD nowrap><FONT size="2">OMB Number: 3235-0145</FONT></TD></TR>
<TR><TD nowrap><FONT size="2">Expires: December 31, 2005</FONT></TD></TR>
<TR><TD nowrap><FONT size="2">Estimated average burden<BR>
hours per response...11</FONT></TD></TR></TABLE>

<BR clear="right">
<BR clear="right">

<P align="center"><FONT size="4">UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</FONT><BR>
<FONT size="3">Washington, D.C. 20549</FONT>

<P align="center"><FONT size="5">SCHEDULE 13D</FONT>

<P align="center"><FONT size="2">Under the Securities Exchange Act of
1934*<BR>
(Amendment No. 1)</FONT>

<P align="center"><FONT size="2">AccuImage Diagnostics Corp.</FONT><BR>
<HR size="1" noshade>
<CENTER><FONT size="2">(Name of Issuer)</FONT></CENTER>

<P align="center"><FONT size="2">Common Stock</FONT><BR>
<HR size="1" noshade>
<CENTER><FONT size="2">(Title of Class of Securities)</FONT></CENTER>

<P align="center"><FONT size="2">004381109</FONT><BR>
<HR size="1" noshade>
<CENTER><FONT size="2">(Cusip Number)</FONT></CENTER>

<P> <CENTER> <P align="center"><FONT size="2">Aviel Faliks</FONT><BR>
<FONT size="2">101 Summer St., Apt. 414</FONT><BR>
<FONT size="2">Stamford, CT 06901</FONT><BR>
<FONT size="2">(646) 296-9480</FONT><BR>
<HR size="1" noshade>
<CENTER><FONT size="2">(Name, Address and Telephone Number of Person<BR>Authorized to Receive Notices and Communications)</FONT></CENTER>
</CENTER>
<P align="center"><FONT size="2">April 1, 2004; July 3, 2004; August 20, 2004; September 24, 2004</FONT><BR>
<HR size="1" noshade>
<CENTER><FONT size="2">(Date of Event Which Requires Filing of this Statement)</FONT></CENTER>
<P>
<FONT size="2">If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of &#167;&#167;240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.</FONT> <FONT face="wingdings">&#111;</FONT>
<P>
<P><FONT size="2">Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See &#167;240.13d-7 for other parties to whom copies are to be sent.</FONT>
<P>
<P><FONT size="2"><SUP>*</SUP></FONT><FONT size="2"> The remainder of this cover page shall be filled out for a reporting person&#146;s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.</FONT>
<P>
<P><FONT size="2">The information required on the remainder of this cover page shall not be deemed to be &#147;filed&#148; for the purpose of Section 18 of the Securities Exchange Act of 1934 (&#147;Act&#148;) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).</FONT>

<P align="center"><FONT size="2">&nbsp;</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="4">
<TR>
<TD width="4%"><FONT size="2">&nbsp;</FONT></TD>
<TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
<TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
<TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
<TD width="28%"><FONT size="2">&nbsp;</FONT></TD>
<TD width="14%"><FONT size="2">&nbsp;</FONT></TD>
<TD width="45%"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
<TD colspan="5"><FONT size="2"><B>CUSIP No. 004381109</B></FONT> </td> <TD colspan="2" align="right"><FONT size="2">Page 2 of 5</FONT> </TD>
</TR>

<TR><TD colspan=7><HR noshade></TD></TR>

<TR>
<TD><FONT size="2">&nbsp;</FONT></TD>
<TD valign=top><FONT size="2">1.</FONT></TD>
<TD valign=top colspan=3><FONT size="2">Name of Reporting Person:<BR>Aviel Faliks</FONT></TD>
<TD valign=top colspan=2><FONT size="2">I.R.S. Identification Nos. of above persons (entities only):<BR>
</FONT></TD>
</TR>

<TR><TD colspan=7><HR noshade></TD></TR>

<TR>
<TD><FONT size="2">&nbsp;</FONT></TD>
<TD valign=top><FONT size="2">2.</FONT></TD>
<TD valign=top colspan=5><FONT size="2">Check the Appropriate Box if a Member of a Group (See Instructions):</FONT></TD>
</TR>

<TR>
<TD><FONT size="2">&nbsp;</FONT></TD>
<TD><FONT size="2">&nbsp;</FONT></TD>
<TD valign=top><FONT size="2">(a)</FONT></TD>
<TD valign=top><FONT face="wingdings">&#111;</FONT></TD>
<TD valign=top colspan=3><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR>
<TD><FONT size="2">&nbsp;</FONT></TD>
<TD><FONT size="2">&nbsp;</FONT></TD>
<TD valign=top><FONT size="2">(b)</FONT></TD>
<TD valign=top><FONT face="wingdings">&#111;</FONT></TD>
<TD valign=top colspan=3><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR><TD colspan=7><HR noshade></TD></TR>

<TR>
<TD><FONT size="2">&nbsp;</FONT></TD>
<TD valign=top><FONT size="2">3.</FONT></TD>
<TD valign=top colspan=5><FONT size="2">SEC Use Only:</FONT></TD>
</TR>

<TR><TD colspan=7><HR noshade></TD></TR>

<TR>
<TD><FONT size="2">&nbsp;</FONT></TD>
<TD valign=top><FONT size="2">4.</FONT></TD>
<TD valign=top colspan=5><FONT size="2">Source of Funds (See Instructions):<BR>PF</FONT></TD>
</TR>

<TR><TD colspan=7><HR noshade></TD></TR>


<TR>
<TD><FONT size="2">&nbsp;</FONT></TD>
<TD valign=top><FONT size="2">5.</FONT></TD>
<TD valign=top colspan=5><FONT size="2">Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e): <FONT face="wingdings">&#111;</FONT> </FONT></TD>
</TR>

<TR><TD colspan=7><HR noshade></TD></TR>

<TR>
<TD><FONT size="2">&nbsp;</FONT></TD>
<TD valign=top><FONT size="2">6.</FONT></TD>
<TD valign=top colspan=5><FONT size="2">Citizenship or Place of Organization:<BR>U.S. Citizen</FONT></TD>
</TR>

<TR><TD colspan=7><HR noshade></TD></TR>

<TR><TD colspan="3" rowspan="8" align="center"><FONT size="2">Number of<BR>Shares<BR>Beneficially<BR>Owned by<BR> Each Reporting<BR>Person With</FONT></TD></TR>

<TR><TD valign=top><FONT size="2">7.</FONT></TD>
<TD valign=top colspan=3><FONT size="2">Sole Voting Power:<BR>34,050,000 shares</FONT></TD></TR>

<TR><TD colspan=4><hr noshade></TD></TR>

<TR><TD valign=top><FONT size="2">8.</FONT></TD><TD valign=top colspan=3> <FONT size="2">Shared Voting Power:<BR>NA</FONT></TD></TR>

<TR><TD colspan=4><hr noshade></TD></TR>

<TR><TD valign=top><FONT size="2">9.</FONT></TD><TD valign=top colspan=3> <FONT size="2">Sole Dispositive Power:<BR>34,050,000 shares</FONT></TD></TR>

<TR><TD colspan=4><hr noshade></TD></TR>

<TR><TD valign=top><FONT size="2">10.</FONT></TD><TD valign=top colspan=3><FONT size="2">Shared Dispositive Power:<BR>NA</FONT></TD></TR>

<TR><TD colspan=7><hr noshade></TD></TR>

<TR><TD><FONT size="2">&nbsp;</FONT></TD>
<TD valign=top><FONT size="2">11.</FONT></TD><TD valign=top colspan=5><FONT size="2">Aggregate Amount Beneficially Owned by Each Reporting Person: <BR>34,050,000 shares</FONT></TD>
</TR>

<TR><TD colspan=7><hr noshade></TD></TR>

<TR><TD><FONT size="2">&nbsp;</FONT></TD>
<TD valign=top><FONT size="2">12.</FONT></TD><TD valign=top colspan=5><FONT size="2">Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):<BR> <FONT face="wingdings">&#111;</FONT> </FONT></TD>
</TR>

<TR><TD colspan=7><hr noshade></TD></TR>

<TR><TD><FONT size="2">&nbsp;</FONT></TD>
<TD valign=top><FONT size="2">13.</FONT></TD><TD valign=top colspan=5><FONT size="2">Percent of Class Represented by Amount in Row (11):<BR>59.4%</FONT></TD></TR>

<TR><TD colspan=7><hr noshade></TD></TR>

<TR><TD><FONT size="2">&nbsp;</FONT></TD>
<TD valign=top><FONT size="2">14.</FONT></TD><TD valign=top colspan=5><FONT size="2">Type of Reporting Person (See Instructions):<BR>IN</FONT></TD></TR>

<TR><TD colspan=7><hr noshade></TD></TR>
</TABLE>

<P align="center"><FONT size="2">2</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%"></TD>
    <TD width="5%"></TD>
    <TD width="30%"></TD>
    <TD width="5%"></TD>
    <TD width="30%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top"><B>CUSIP No.&nbsp;004381109</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>SCHEDULE 13D</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">Page 3 of 5 Pages</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="left" style="font-size: 10pt"><B>Item&nbsp;1. Security and Issuer.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Statement relates to the common stock, no par value (the &#147;Common
Stock&#148;), of AccuImage Diagnostics Corp. (the &#147;Company&#148;), whose offices are
located at 400 Oyster Point Boulevard, Suite&nbsp;201, South San Francisco,
California 94080.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;2. Identity and Background.</B>



<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Aviel Faliks</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>101 Summer Street, Apt. 414, Stamford, CT 06901.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Employer: A-Squared Management, LLC; Financial Management; Research
Analyst.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the last five years, Mr.&nbsp;Faliks has not been convicted in any
criminal proceeding (excluding traffic violations or similar
misdemeanors).</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the last five years, Mr.&nbsp;Faliks has not been a party to a civil
proceeding of a judicial or administrative body of competent jurisdiction
resulting in his being subject to a judgment, decree or final order
enjoining future violations of, or prohibiting or mandating activities
subject to, federal or state securities laws or finding any violation with
respect to such laws.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Mr.&nbsp;Faliks is a citizen of the United States.</TD>
</TR>

</TABLE>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;3. Source and Amount of Funds or Other Consideration.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;5, 2004, the Company&#146;s Board of Directors (the &#147;Board&#148;) met and
agreed to grant Mr.&nbsp;Faliks stock as compensation for his services as Chief
Executive Officer of the Company. The shares were to be granted to Mr.&nbsp;Faliks
each quarter and be valued at approximately $30,000 as of the pricing dates of
December&nbsp;15, 2003; March&nbsp;15, 2004; June&nbsp;15, 2004; and September&nbsp;15, 2004. On
April&nbsp;1, 2004, Mr.&nbsp;Faliks was awarded 750,000 shares by the compensation
committee, pursuant to the March&nbsp;5, 2004 Board action. On July&nbsp;3, 2004, Mr.
Faliks was awarded 375,000 shares by the compensation committee, pursuant to
the March&nbsp;5, 2004 Board action. On September&nbsp;24, 2004, Mr.&nbsp;Faliks was awarded
375,000 shares by the compensation committee, pursuant to the March&nbsp;5, 2004
Board action.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;5, 2004 and August&nbsp;17, 2004 the Board also approved the sale of
additional shares to Mr.&nbsp;Faliks at a price of $0.04 per share. On August&nbsp;20,
2004, Mr.&nbsp;Faliks purchased 7,500,000 shares pursuant to the March&nbsp;5, 2004 and
August&nbsp;17, 2004 Board action.


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%"></TD>
    <TD width="5%"></TD>
    <TD width="30%"></TD>
    <TD width="5%"></TD>
    <TD width="30%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top"><B>CUSIP No.&nbsp;004381109</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>SCHEDULE 13D</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">Page 4 of 5 Pages</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="left" style="font-size: 10pt"><B>Item&nbsp;4. Purpose of Transaction.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The purchase of Common Stock of the Company was made as a personal
investment by Mr.&nbsp;Faliks. Shares received as compensation were issued in
consideration of Mr.&nbsp;Faliks services rendered as the Company&#146;s Chief Executive
Officer.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;5. Interest in Securities of the Issuer.</B>



<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Mr.&nbsp;Faliks individually beneficially owns 34,050,000 shares of the
Company&#146;s Common Stock (approximately 59.4% of the shares of the Company&#146;s
Common Stock). The foregoing percentage is calculated based upon
57,336,295 shares of Common Stock outstanding.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Mr.&nbsp;Faliks has the sole power to vote and sole power to direct the
34,050,000 shares of the Company&#146;s Common Stock.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>On September&nbsp;24, 2004, Mr.&nbsp;Faliks was awarded 375,000 shares by the
compensation committee, pursuant to the March&nbsp;5, 2004 Board minutes.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not applicable.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not applicable.</TD>
</TR>

</TABLE>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;6. Contracts, Arrangements, Understandings or Relationships with Respect
to Securities of the Issuer.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Faliks presently has no other contracts, arrangements, understandings
or relationships with any other person with respect to any of the Company&#146;s
securities, including but not limited to transfer or voting of any of the
securities, finder&#146;s fees, joint ventures, loan or option arrangements, puts or
calls, guarantees of profits, division of profits or loss, or the giving or
withholding of proxies.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;7. Material to be Filed as Exhibits.</B>



<P align="left" style="font-size: 10pt">None



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%"></TD>
    <TD width="5%"></TD>
    <TD width="30%"></TD>
    <TD width="5%"></TD>
    <TD width="30%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top"><B>CUSIP No.&nbsp;004381109</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>SCHEDULE 13D</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">Page 5 of 5 Pages</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top">&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>Dated:  September 30, 2004&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000">/s/ Aviel Faliks
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">Aviel Faliks&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SUBMISSION>
